Published in Cancer Res on November 15, 1989
Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev (2007) 3.45
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell (2011) 1.96
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest (2009) 1.83
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell (2013) 1.72
Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish. Proc Natl Acad Sci U S A (2007) 1.70
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet (2014) 1.49
Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep (2013) 1.24
Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc Natl Acad Sci U S A (2011) 1.20
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell (2005) 1.05
Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model. Dis Model Mech (2013) 1.02
Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS Genet (2013) 0.94
Endogenous Voltage Potentials and the Microenvironment: Bioelectric Signals that Reveal, Induce and Normalize Cancer. J Clin Exp Oncol (2013) 0.90
Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer (2015) 0.89
A DNA transposon-based approach to validate oncogenic mutations in the mouse. Proc Natl Acad Sci U S A (2008) 0.88
Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis. Development (2013) 0.88
MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget (2014) 0.88
Zebrafish models of p53 functions. Cold Spring Harb Perspect Biol (2010) 0.88
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One (2013) 0.86
Atypical protein kinase Cs are the Ras effectors that mediate repression of myogenic satellite cell differentiation. Mol Cell Biol (2002) 0.86
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res (2013) 0.85
Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells. J Cell Biol (2001) 0.85
The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish. PLoS One (2013) 0.85
Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol (2012) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet (2015) 0.83
Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. Br J Cancer (2000) 0.82
C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells. Cancer Med (2016) 0.81
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma. PLoS One (2014) 0.81
RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. Int J Oncol (2012) 0.81
Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis. Acta Neuropathol Commun (2014) 0.80
New insights into the origin and the genetic basis of rhabdomyosarcomas. Cancer Cell (2011) 0.79
Zebrafish models of rhabdomyosarcoma. Methods Cell Biol (2011) 0.78
Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death. Front Oncol (2015) 0.78
Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. PLoS One (2015) 0.78
Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma. Am J Med Genet A (2016) 0.77
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest (2015) 0.77
Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations. Mol Pathol (1999) 0.76
Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM. Br J Cancer (1991) 0.76
Uncovering metabolism in rhabdomyosarcoma. Cell Cycle (2016) 0.75
Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets. Curr Genomics (2016) 0.75
MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line. PLoS One (2015) 0.75
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Mechanism of met oncogene activation. Cell (1986) 4.20
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Drip breast milk: it's composition, collection and pasteurization. Early Hum Dev (1977) 3.47
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab (1995) 3.34
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry (1989) 3.09
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
p53 mutations in BRCA1-associated familial breast cancer. Lancet (1997) 2.69
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol (2000) 2.67
Comparative study of human and rat mammary tumorigenesis. Lab Invest (1990) 2.58
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Pathol (1992) 2.54
Natural history of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 2.52
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
Predictors of laparoscopic complications after formal training in laparoscopic surgery. JAMA (1993) 2.37
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Imaging features of retroperitoneal and pelvic schwannomas. Clin Radiol (2005) 2.32
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int (2003) 2.29
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
A breakdown of symmetry in the folding transition state of protein L. J Mol Biol (2000) 2.26
Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol (1999) 2.16
Chromosome mediated gene transfer of six DNA markers linked to the cystic fibrosis locus on human chromosome seven. Nucleic Acids Res (1986) 2.16
Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J (1995) 2.14
Management of metastatic melanoma during pregnancy. BMJ (1998) 2.10
Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res (1982) 2.07
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene (1994) 2.05
Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene (1989) 1.92
New method for detecting cellular transforming genes. Science (1982) 1.92
Curcumin is an in vivo inhibitor of angiogenesis. Mol Med (1998) 1.81
Misidentified cell. Nature (1989) 1.81
Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet (1992) 1.81
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) (1997) 1.77
Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol (2008) 1.76
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene (1994) 1.75
Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst (1999) 1.73
Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg (2005) 1.71
Human breast development. J Mammary Gland Biol Neoplasia (2000) 1.71
Aggressive angiomyxoma. A report of four cases occurring in men. Am J Surg Pathol (1992) 1.69
A genetic association for cigarette smoking behavior. Health Psychol (1999) 1.69
Breast diseases: color Doppler US in differential diagnosis. Radiology (1993) 1.67
Head and neck sarcomas: prognostic factors and implications for treatment. Br J Cancer (1993) 1.67
Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol (2005) 1.66
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit. Clin Infect Dis (1997) 1.57
An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. Science (1984) 1.56
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem (1996) 1.56
Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene (1990) 1.56
Myofibrosarcoma: a clinicopathologic study. Am J Surg Pathol (2001) 1.54
Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol (1998) 1.53
Gastric carcinoma presenting with testicular metastasis. Br J Urol (1994) 1.52
Prognostic index for extremity soft tissue sarcomas with isolated local recurrence. Ann Surg Oncol (2001) 1.52
Tpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complex. J Cell Biol (1994) 1.52
Nipple confusion--who is confused? J Pediatr (1996) 1.50
Appendicovesicostomy: the mitrofanoff procedure-a 15-year perspective. J Urol (2000) 1.50
Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol (2009) 1.50
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol (2001) 1.49
Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett (1995) 1.48
Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer (2005) 1.46
Head and neck liposarcoma. Cancer (1995) 1.45
The molecular pathology of small round-cell tumours--relevance to diagnosis, prognosis, and classification. J Pathol (1996) 1.45
Real-time DNA binding measurements of the ETS1 recombinant oncoproteins reveal significant kinetic differences between the p42 and p51 isoforms. Protein Sci (1994) 1.44
Reducing time in bed after cardiac catheterization (TIBS II) Am J Crit Care (1996) 1.43
Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur J Endocrinol (1997) 1.43
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene (1998) 1.41
Additional copies of 1q in sequential samples from a phyllodes tumor of the breast. Cancer Genet Cytogenet (1995) 1.40
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer (1998) 1.40
Tooth induction in chick epithelium: expression of quiescent genes for enamel synthesis. Science (1980) 1.39
Outpatient vulval biopsy--a note of caution. Br J Obstet Gynaecol (1995) 1.38
Primary hyperparathyroidism: an unusual cause of cervical myelopathy. A case report. J Bone Joint Surg Am (2001) 1.38
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer (1986) 1.36
Limitations of surgery in the treatment of retroperitoneal sarcoma. Br J Surg (1991) 1.36
A psychophysiological study of nightmares and night terrors. The suppression of stage 4 night terrors with diazepam. Arch Gen Psychiatry (1973) 1.35
Characterization of the human cell line TE671. Carcinogenesis (1989) 1.34
Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res (1998) 1.33
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. J Virol (1999) 1.32
Improved immunohistochemical localization of tissue antigens using modified methacarn fixation. J Histochem Cytochem (1985) 1.32
Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene (2003) 1.32
Compartment switching of WNT-2 expression in human breast tumors. Cancer Res (1996) 1.32